Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% ...

Pfizer’s battle over the safety label for its birth control injection has finally come to a close. The pharma giant announced that the Food and Drug Administration approved its new safety warning ...

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

As Autumn rolls around, parents in the US who want to vaccinate their young children against COVID-19 may find it trickier to do so this year. According to the US Centres for Disease Control and ...

Pfizer (NYSE:PFE) received FDA Priority Review to expand HYMPAVZI to younger hemophilia patients and those with inhibitors.

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Pfizer's strength lies in its integrated approach to drug development, from discovery to clinical trials, and finally, ...